TrialBlood2014

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

Arne Kolstad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.